Search
Nilutamide
go.drugbank.com/drugs/DB00665ApprovedInvestigationalNilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors). … Prostate cancer is mostly androgen-dependent and can be treated with surgical or chemical castration. To date, antiandrogen monotherapy has not consistently been shown to be equivalent to castration.
Alteplase
go.drugbank.com/drugs/DB00009ApprovedInvestigational[L43125] It cleaves plasminogen to form plasmin, an enzyme involved in the degradation of fibrin clots. … [A252345,L43125] It was first approved by the FDA in 1987 for the management of thromboembolic disease, including acute myocardial infarction (AMI).
Synonyms: t-PA, t-plasminogen activatorCasimersen
go.drugbank.com/drugs/DB14984ApprovedInvestigational[A218171, A218176, A229988] The application of antisense oligonucleotides in DMD patients with specific mutations allows for exon skipping to produce truncated BMD-like dystrophin proteins, which restore … A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production.
Categories: Compounds used in a research, industrial, or household settingEnflurane
go.drugbank.com/drugs/DB00228ApprovedVet approvedWithdrawnIn addition, it is known to cause increased cardio depressant effects when compared to other inhaled anesthetics.[A202022] … Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.
Voxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … to 20 million others worldwide.
Polysilicone-15
go.drugbank.com/drugs/DB11271ApprovedThe compound is a colorless to pale yellow viscous liquid which is soluble in organic solvents of medium polarity and insoluble in water [L2796, L2797, L2799, F87, F88, F89]. … It is the first polymeric UVB filer consisting of chromophores attached to a silicone backbone [L2796, L2797, L2799, F87, F88, F89].
Deoxycholic acid
go.drugbank.com/drugs/DB03619ApprovedInvestigationalIn April 2015, deoxycholic acid was approved by the FDA for the treatment submental fat to improve aesthetic appearance and reduce facial fullness or convexity. … It is marketed under the brand name Kybella by Kythera Biopharma and is the first pharmacological agent available for submental fat reduction, allowing for a safer and less invasive alternative than surgical
Tapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigational[L47291] Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options. … [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalIt was developed to alleviate Canada's multi-year shortage of BCG vaccine, and is expected to be available by mid-2021.[L32734] … thought to work by stimulating a local immune and inflammatory response in the bladder.
Promethazine
go.drugbank.com/drugs/DB01069ApprovedInvestigational[A189901] Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.
Categories: Antihistamines for Topical Use, Antihistamines for Systemic Use